Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2015: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2013: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
Outline of Final Research Achievements |
Allergen-specific immunotherapy (AIT) is the only curative treatment for allergic disorders, but current AIT using crude allergen extract has problems such as risk for side effects and poor clinical outcomes. In this study, we aimed to develop a molecular diagnostic system of allergy for effective AIT. Here, we showed a successful and comprehensive production of 26 derivatives from 23 house dust allergens as recombinant proteins. We established the molecular diagnostic system using the recombinant allergen-molecules to elucidate individual IgE-binding allergen profiles enable us to develop a personalized AIT vaccine for individuals and predict progression of house dust mite allergy.
|